CPL302-253

CPL302-253 (150 nM-4 μM; assay-specific durations) inhibits biomarker expression and B cell proliferation in the activated CD19 B cell + PBMC BT co-culture system, with only minimal, low-magnitude activity in one other non-immune primary cell co-culture system^[1].
CPL302-253 (1-10000 nM; 1 h pre-incubation, then 72 h with stimulants) inhibits CD25 expression and proliferation in activated primary human CD19⁺ B cells, with significant effects observed at concentrations as low as 10 nM^[1].
CPL302-253 (1-10000 nM; 48 h) inhibits IFNγ production in activated primary human CD8⁺ T cells, with significant effects observed at concentrations as low as 1 nM^[1].
CPL302-253 (1 μM; 72 h) inhibits IL-33 expression in A549 lung epithelial cells co-cultured with activated primary human CD8⁺ T cells^[1].
CPL302-253 (1 μM; 30 min pre-incubation, then 6 h with stimulants) inhibits IL-8 production in primary human neutrophils stimulated with either CSE or LPS^[1].
CPL302-253 (15 min before priming/stimulation, with total assay duration including 2 h post-LPS incubation), co-administered with dexamethasone, reduces ROS accumulation in primary human neutrophils activated with GM-CSF and LPS^[1].
CPL302-253 (1 nM-100000 nM; 25 min) inhibits basophil activation, as measured by CD63 expression, with an IC₅₀ of 36 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.